Analysis of the structure of consumption of antiplatelet drugs in the Russian pharmaceutical market: 2014-2016

• Main Authors: S. K. Zyryanov, E. V. Dumchenko
• Format: Article
• Language: Russian
• Published: Izdatelstvo OKI 2018-05-01
• Series: Качественная клиническая практика
• Subjects: исследование потребления лекарств; обзор потребления лекарственных средств; фармацевтический рынок; антитромбоцитарные препараты; тиклопидин; клопидогрел; тикагрелор; россия; drug utilization research; survey of drug usage; survey of drug consumption; pharmaceutical market; antiplatelet drugs; ticlopidine; clopidogrel; ticagrelor; russia
• Online Access: https://www.clinvest.ru/jour/article/view/85
• ISSN: 2588-0519; 2618-8473

This article analyzes the volume of the Russian pharmaceutical market of antiplatelet drugs in the period 2014-2016. 80% of patients take clopidogrel generics, giving preference to Zilt®. Among the original drugs, the leaders of consumption are Plavix® and Coplavix® - in 2016 year 16%. In the structure of consumption of antiplatelet drugs, the share of original drugs as a whole account for about 60% of consumption in value terms, which is about 25% in packs. Clopidogrel generics (54% in value terms and 85% in natural terms) pass through the state segment, which means that most of the original drugs are purchased by patients through the retail pharmacy network, despite their high cost.